The American Cancer Society National Lung Cancer Roundtable strategic plan: Lung cancer in women
Lung cancer in women is a modern epidemic and represents a global health crisis. Cigarette smoking remains the most important risk factor for lung cancer in all patients and, among women globally, rates of smoking continue to increase. Although some data exist supporting sex-based differences across the continuum of lung cancer, there is currently a dearth of research exploring the differences in risk, biology, and treatment outcomes in women. Consequently, the American Cancer Society National Lung Cancer Roundtable recognizes the urgent need to promote awareness and future research that will close the knowledge gaps regarding lung cancer in women. To this end, the American Cancer Society National Lung Cancer Roundtable Task Group on Lung Cancer in Women convened a summit undertaking the following to: (1) summarize existing evidence and identify knowledge gaps surrounding the epidemiology, risk factors, biologic differences, and outcomes of lung cancer in women; (2) develop and prioritize research topics and questions that address research gaps and advance knowledge to improve quality of care of lung cancer in women; and (3) propose strategies for future research. PLAIN LANGUAGE SUMMARY: Lung cancer is the leading cause of cancer mortality in women, and, despite comparatively lower exposures to occupational and environmental carcinogens compared with men, disproportionately higher lung cancer rates in women who ever smoked and women who never smoked call for increased awareness and research that will close the knowledge gaps regarding lung cancer in women.
Authors
- Patricia N. watkins
- Louise M. Henderson (ORCID: https://orcid.org/0000-0001-8356-9267)
- Claudia I. Henschke (ORCID: https://orcid.org/0000-0002-6085-5305)
- Ahmedin Jemal (ORCID: https://orcid.org/0000-0002-0000-4111)
- Robert Allen Smith (ORCID: https://orcid.org/0000-0003-3344-2238)
- Francine L. Jacobson (ORCID: https://orcid.org/0000-0002-0716-2198)
- Jill M. Siegfried
- Juan P. Wisnivesky (ORCID: https://orcid.org/0000-0003-0299-4582)
- Linda W. Martin (ORCID: https://orcid.org/0000-0002-7951-5677)
- Lori C. Sakoda (ORCID: https://orcid.org/0000-0002-0900-5735)
- Joan H. Schiller (ORCID: https://orcid.org/0000-0003-0990-1211)
- Kim Lori Sandler (ORCID: https://orcid.org/0000-0003-2989-248X)
- M. Patricia Rivera (ORCID: https://orcid.org/0000-0003-3827-5010)
- Karen Kelly (ORCID: https://orcid.org/0000-0002-2235-6636)
- Leah M. Backhus (ORCID: https://orcid.org/0000-0002-4553-1003)
- G. Hollenbeck
- Andrea Wolf
- Ching‐Fei Chang
- Elridge D. Proctor
- Shonta R. Chambers
Institutions
- University of North Carolina at Chapel Hill (US)
- University of Southern California (US)
- Brigham and Women's Hospital (US)
- American Cancer Society (US)
- University of Minnesota (US)
- Kaiser Permanente (US)
- Harvard University (US)
- University of Rochester Medical Center (US)
- Lung Cancer Research Foundation (US)
- Phoenix VA Health Care System (US)
- Go2 for Lung Cancer (US)
- Patient Advocate Foundation (US)
- University of Virginia (US)
- University of California, Davis (US)
- Vanderbilt University Medical Center (US)
- Stanford University (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Cancer
- Published
- 2024-09-20
- DOI
- https://doi.org/10.1002/cncr.35083
- Citations
- 10
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 4.19
Funders
- Amgen
- Bristol-Myers Squibb
- AstraZeneca
- Sanofi
- Gilead Sciences
- Regeneron Pharmaceuticals
- Novocure
- Genentech
- Foundation Medicine
- Daiichi Sankyo Europe